Crystal structure of an anti‐idiotype variable lymphocyte receptor. Issue 12 (4th December 2017)

• Record Type: Journal Article
• Authors: Collins, Bernard C.; Nakahara, Hiro; Acharya, Sharmistha; Cooper, Max D.; Herrin, Brantley R.; Wilson, Ian A.
• Is Part Of: Acta crystallographica. Volume 73:Issue 12(2017:Dec.)
• Page Start: 682
• Page End: 687
• Publication Date: 2017-12-04
• Subjects: structural biology -- crystallography -- immunology -- antibodies -- B‐cell receptors -- anti‐idiotype -- leucine‐rich repeats -- variable lymphocyte receptors; Crystallography -- Periodicals; Crystals -- Periodicals; 548
• DOI: 10.1107/S2053230X1701620X
• Languages: English
• ISSNs: 2053-230X

Abstract

Abstract : The crystal structure of an anti‐idiotype VLR, VLR39, at 1.5 Å resolution is presented and compared with those of other protein‐specific VLRs. Binding studies with purified components confirms a VLR39–Fv interaction. Abstract : Variable lymphocyte receptors (VLRs), the leucine‐rich repeat (LRR)‐based antigen receptors of jawless fish, have great utility in a wide variety of biochemical and biological applications, similar to classical Ig‐based antibodies. VLR‐based reagents may be particularly useful when traditional antibodies are not available. An anti‐idiotype lamprey VLR, VLR39, has previously been identified that recognizes the heavy‐chain CDR3 of the B‐cell receptor (BCR) of a leukemic clone from a patient with chronic lymphocytic leukemia (CLL). VLR39 was used successfully to track the re‐emergence of this clone in the patient following chemotherapy. Here, the crystal structure of VLR39 is presented at 1.5 Å resolution and compared with those of other protein‐specific VLRs. VLR39 adopts a curved solenoid fold and exhibits substantial structural similarity to other protein‐binding VLRs. VLR39 has a short LRRCT loop that protrudes outwards away from the concave face and is similar to those of its protein‐specific VLR counterparts. Analysis of the VLR39–BCR interaction by size‐exclusion chromatography and biolayer interferometry using the scFv version of the BCR confirms that VLR39 recognizes the BCR Fv region. Such VLR‐based reagents may be useful for identifying and monitoring leukemia in CLL patients and in other clinical diagnostic assays.